EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Metformin: Historical Origins, Mechanisms of Action, and Emerging Clinical Applications

Ye Hu, Xinmiao Zhang, Changwei Yang, Xiaohong Wu iD, Xiao Ye, Jicheng Yu, Yunbei Yang

Diabetes/Metabolism Research and Reviews · 2026

DOI: 10.1002/dmrr.70171 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Diabetes/Metabolism Research and Reviews, 2026. Verfasst von Ye Hu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Geriatric Medicine Center, Zhejiang Provincial People's Hospital (Affiliated People's Hospital, Hangzhou Medical College…. Hauptthemen laut MEDLINE: Metformin, Hypoglycemic Agents, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 503 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Medical Science and Technology Project of Zhejiang Province, Basic Scientific Research Funds of Department of Education of Zhejiang Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metformin is derived from the plant Galega officinalis with the blood‐glucose‐lowering properties. Although its early development was hindered by the toxicity issues associated with other guanidine derivatives and the rise of insulin therapies, it ultimately established its position as a first‐line oral hypoglycemic agent for addressing insulin resistance and managing hyperglycemia through extensive clinical validation. With a nearly 70‐year history in diabetes treatment, the mechanisms by which metformin modulates blood glucose have been widely studied and refined. Recent investigations into combination therapies, fixed‐dose formulations, and novel applications underscores a broader therapeutic potential beyond glycemic control. This paper aims to review the development trajectory of metformin, consolidate the latest evidence for its clinical benefits, and critically appraise its future directions and constraints.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MetforminHypoglycemic AgentsDiabetes Mellitus, Type 2HumansAnimalsBlood GlucoseInsulin Resistance

Substanzen

MetforminHypoglycemic AgentsBlood Glucose

Autor:innen und Institutionen

  • Department of Endocrinology, Geriatric Medicine Center, Zhejiang Provincial People's Hospital (Affiliated People's Hospital, Hangzhou Medical College), Hangzhou, China.
  • Department of Pharmacy, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
  • State Key Laboratory of Advanced Drug Delivery and Release Systems, School of Pharmacy, Zhejiang University, Hangzhou, China.
  • Zhejiang Key Laboratory of New Drug Intelligent Innovation for Metabolic Diseases, Zhejiang University, Hangzhou, China.
  • Jinhua Institute of Zhejiang University, Jinhua, China.
  • Department of General Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China.

ORCID-Profile: Xiaohong Wu

Förderung

  • National Natural Science Foundation of China
  • Medical Science and Technology Project of Zhejiang Province
  • Basic Scientific Research Funds of Department of Education of Zhejiang Province

Zitieren

APA

Hu, Y., Zhang, X., Yang, C., Wu, X., Ye, X., Yu, J., & Yang, Y. (2026). Metformin: Historical Origins, Mechanisms of Action, and Emerging Clinical Applications. Diabetes/Metabolism Research and Reviews. https://doi.org/10.1002/dmrr.70171

Vancouver

Hu Y, Zhang X, Yang C, Wu X, Ye X, Yu J, et al. Metformin: Historical Origins, Mechanisms of Action, and Emerging Clinical Applications. Diabetes/Metabolism Research and Reviews. 2026. doi:10.1002/dmrr.70171

BibTeX
@article{Hu2026,
  author = {Hu, Ye and Zhang, Xinmiao and Yang, Changwei and Wu, Xiaohong and Ye, Xiao and Yu, Jicheng and Yang, Yunbei},
  title = {Metformin: Historical Origins, Mechanisms of Action, and Emerging Clinical Applications},
  journal = {Diabetes/Metabolism Research and Reviews},
  year = {2026},
  doi = {10.1002/dmrr.70171}
}
Kostenlos starten →